ホーム › びまん性大細胞型B細胞リンパ腫 › オレゴン
オレゴンにおけるびまん性大細胞型B細胞リンパ腫の臨床試験
オレゴン内の拠点で、びまん性大細胞型B細胞リンパ腫に関する15件の研究が参加者を募集しています。
オレゴン内の都市
公式研究テキスト（英語）
Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma
- Providence Portland Medical Center, Portland
- Providence Saint Vincent Medical Center, Portland
被験者募集中第2相
18歳以上 · 全性別 · 2026/10/01更新 · NCT06649812A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
- Providence Portland Medical Center ( Site 0120), Portland
- Providence Oncology and Hematology Clinic Westside ( Site 0179), Portland
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/25更新 · NCT06890884A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
- Kaiser Permanente Interstate Medical Office - Central ( Site 0181), Portland
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/25更新 · NCT06717347Vaccine Responses in Patient With Multiple Myeloma and Non-Hodgkin Lymphoma After CAR-T Treatment
- OHSU Knight Cancer Institute, Portland
被験者募集中観察研究
18歳以上 · 全性別 · 2026/09/23更新 · NCT06784167A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
- Oregon Health & Science University (OHSU), Portland
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/22更新 · NCT07226843Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
- Oregon Health and Science University ( Site 1004), Portland
被験者募集中第1/2相
6 Months – 25 Years · 全性別 · 2026/09/17更新 · NCT06395103Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL
- Oncology Associates of Oregon, P.C, Eugene
- Providence Portland Medical Center, Portland
- Providence St. Vincent Medical Center, Portland
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/11更新 · NCT06806033Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
- Oncology Associates of Oregon, Eugene
- Oregon Health and Science University, Portland
被験者募集中第2相
18歳以上 · 全性別 · 2026/08/31更新 · NCT06500273Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
- Oregon Health & Science University, Portland
被験者募集中第1/2相
13歳〜90歳 · 全性別 · 2026/08/06更新 · NCT06533579Lentiviral Gene Therapy (Zamtocabtagene Autoleucel) LTFU
- Oregon Health and Science University Knight Cancer Institute, Portland
被験者募集中観察研究
18歳以上 · 全性別 · 2026/08/05更新 · NCT06116110DALY II USA/ MB-CART2019.1 for DLBCL
- Oregon Health and Science University Knight Cancer Institute, Portland
被験者募集中第2相
18歳以上 · 全性別 · 2026/07/13更新 · NCT04792489Mosunetuzumab With Chemotherapy for the Treatment of Patients With Untreated C-Myc Rearrangement Positive High Grade B Cell Lymphoma or Diffuse Large B Cell Lymphoma
- OHSU Knight Cancer Institute, Portland
被験者募集中第1/2相
18歳〜75歳 · 全性別 · 2026/07/07更新 · NCT06249191Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
- Providence Newberg Medical Center, Newberg
- Providence Willamette Falls Medical Center, Oregon City
- Providence Portland Medical Center, Portland
- 他2件
被験者募集中第2相
18歳以上 · 全性別 · 2026/02/02更新 · NCT05633615Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment
- Providence Newberg Medical Center, Newberg
- Providence Willamette Falls Medical Center, Oregon City
- Providence Portland Medical Center, Portland
- 他1件
被験者募集中第2相
18歳以上 · 全性別 · 2025/10/20更新 · NCT05890352A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies
- Oregon Health & Science University, Portland
被験者募集中第1相
18歳以上 · 全性別 · 2025/10/02更新 · NCT05780034ClinicalTrials.govより、2026/10/02時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。